These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 15646829)
1. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening. Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829 [TBL] [Abstract][Full Text] [Related]
2. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709 [TBL] [Abstract][Full Text] [Related]
3. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women. Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468 [TBL] [Abstract][Full Text] [Related]
4. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less. Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102 [TBL] [Abstract][Full Text] [Related]
6. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Muto MG; Cramer DW; Brown DL; Welch WR; Harlow BL; Xu H; Brucks JP; Tsao SW; Berkowitz RS Gynecol Oncol; 1993 Oct; 51(1):12-20. PubMed ID: 8244166 [TBL] [Abstract][Full Text] [Related]
7. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital]. Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203 [TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240 [TBL] [Abstract][Full Text] [Related]
9. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Strigini FA; Gadducci A; Del Bravo B; Ferdeghini M; Genazzani AR Gynecol Oncol; 1996 Apr; 61(1):68-72. PubMed ID: 8626120 [TBL] [Abstract][Full Text] [Related]
10. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086 [TBL] [Abstract][Full Text] [Related]
11. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S; Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524 [TBL] [Abstract][Full Text] [Related]
12. [Association of ovarian tumors with CA-125]. Martínez-Acosta JE; Olguín-Cruces VA Rev Med Inst Mex Seguro Soc; 2016; 54 Suppl 3():S230-S237. PubMed ID: 27855043 [TBL] [Abstract][Full Text] [Related]
13. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951 [TBL] [Abstract][Full Text] [Related]
14. Screening for ovarian cancer. Quinn MA Aust Fam Physician; 2001 Jun; 30(6):530-4. PubMed ID: 11458578 [TBL] [Abstract][Full Text] [Related]
15. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302 [TBL] [Abstract][Full Text] [Related]
16. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Kramer BS; Gohagan J; Prorok PC; Smart C Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681 [TBL] [Abstract][Full Text] [Related]
17. Preoperative assessment of ovarian tumors by CA 125 measurement and transvaginal color Doppler ultrasound. Kupesić S; Vujisić S; Kurjak A; Mihaljević D; Radosević S Acta Med Croatica; 2002; 56(1):3-10. PubMed ID: 12455447 [TBL] [Abstract][Full Text] [Related]
18. [Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients]. Grzybowski W; Beta J; Fritz A; Durczyński A; Bidziński M; Grabiec M; Jakimiuk AJ Ginekol Pol; 2010 Jul; 81(7):511-5. PubMed ID: 20825052 [TBL] [Abstract][Full Text] [Related]
19. [Is it possible to have organized screening for ovarian cancer?]. Navone R; Montanari G Pathologica; 2003 Apr; 95(2):67-70. PubMed ID: 12768874 [No Abstract] [Full Text] [Related]
20. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]